Author:
Dalwadi Dhwanil A.,Kim Seongcheol,Amdani Shahnawaz M.,Chen Zhenglan,Huang Ren-Qi,Schetz John A.
Reference95 articles.
1. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase;Young;Antimicrob. Agents Chemother.,1995
2. WHO, Consolidated guidelines on the use of antiretroviral drug for the treatment and preventing HIV infection. Recommendations for a public health approach. 2013, 2015, 272.
3. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring;Gutierrez;Clin. Infect. Dis.,2005
4. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs: efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults;Cohen;AIDS,2014
5. Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naive, HIV-1-infected patients at 48 weeks;Mills;HIV Med.,2013
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献